SCHEMBL4209481

SCHEMBL4209481

COc1ccc(NS(=O)(=O)c2ccc(F)cc2F)c2c1C[C@@H](N(C)C)CO2

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.48
QRFPR Q96P65 1/20 0.48
KCNH2 Q12809 1/20 0.42
AXL P30530 1/20 0.41
POLB P06746 2/20 0.41
HTR1A P08908 3/20 0.40
SLC6A4 P31645 3/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 1/20 0.40
CCR2 P41597 1/20 0.39
PIK3CA P42336 2/20 0.39
PIK3R1 P27986 1/20 0.39
ACLY P53396 1/20 0.38
HTR7 P34969 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PI4KA P42356 1/20 0.37
PIK3CG P48736 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202949 0.93 HTR6 (0.48) HTR6QRFPRAXLPOLBHTR1A
SCHEMBL4197760 0.91 HTR6 (0.51) HTR6QRFPRPOLBHTR1ASLC6A4
SCHEMBL4204347 0.91 HTR6 (0.47) HTR6QRFPRLMNAACLY
SCHEMBL4212688 0.90 HTR6 (0.47) HTR6QRFPRPOLBHTR1ASLC6A4
SCHEMBL4207476 0.90 HTR6 (0.46) HTR6QRFPRPOLBHTR1ASLC6A4
SCHEMBL4202359 0.90 HTR6 (0.45) HTR6QRFPRPOLBHTR1ASLC6A4
SCHEMBL4199481 0.89 HTR6 (0.44) HTR6QRFPRPOLBHTR1ASLC6A4
SCHEMBL4207697 0.89 HTR6 (0.43) HTR6QRFPRPOLBHTR1ASLC6A4
SCHEMBL4207623 0.89 HTR6 (0.45) HTR6QRFPRPOLBGAALMNA
SCHEMBL4202391 0.88 HTR6 (0.48) HTR6QRFPRHTR1ASLC6A4ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885KCNH2 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.